Join the Januvia group to help and get support from people like you.
Januvia News
Major Drug Companies Agree to Price Negotiations With U.S. Government
TUESDAY, Oct. 3, 2023 – Pharmaceutical companies that make the 10 prescription drugs chosen to be the first for price negotiations for Medicare patients have agreed to talks with the government. The...
FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...
FDA Medwatch Alert: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain
ISSUE: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and...
FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas
ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...
Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia
Princeton, N.J. (April 9, 2012) /PRNewswire/ - Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin]...
FDA Approves Combination Therapy Juvisync
SILVER SPRING, Md., Oct. 7, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription...
Ask a question
To post your own question to this support group, sign in or create an account.